Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Roche has secured its first regulatory approval for mosunetuzumab, a first-in-class CD20xCD3 bispecific antibody, as a treatment for patients with follicular lymphoma (FL) in the EU.

Roche is on the brink of its first regulatory approval for what could be the first bispecific antibody targeting CD3 and CD20 – mosunetuzumab – after getting a positive opinion for the drug ...

A number of additional approaches to the treatment of B-cell malignancies are in the pipeline, including the T cell bispecific antibodies, mosunetuzumab 11 and CD20-TCB 12. Our aim is to optimise ...

Olszewski’s funding will support his work investigating mosunetuzumab with lenalidomide augmentation as first-line therapy for patients with follicular and marginal zone lymphomas. Researchers ...

Our pipeline also includes RG6299 (ASO factor B), an antisense oligonucleotide therapy being investigated in people with primary immunoglobulin A nephropathy at high risk of progression, Lunsumio ...

Lunsumio U.S. Indication Lunsumio® (mosunetuzumab-axgb) is a prescription medicine used to treat adults with follicular lymphoma whose cancer has come back or did not respond to previous ...

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced the appointment of Suyasha Gupta as Senior ...

Her experience spans multiple indications (renal cell and bladder cancer, follicular lymphoma) and molecules (Atezolizumab, Mosunetuzumab). Her strength in clinical development also stems from her ...